IGF2 overexpression or MET amplification is also associated with primary resistance to cetuximab in CRC PDX models, which could potentially be overcome by a combination of IGF2 and MET inhibitors [129,130,131,132]. Here, IGF2 is linked to colorectal carcinoma.